What do systematic reviews say?

492 questions · 535 findings · 56 reviews · Hypertension

Sort:Best matchNewestHighest certainty Download CSV

No studies found 37 · 6.9%GRADE not reported 34 · 6.4%Very low 91 · 17%Low 161 · 30.1%Moderate 136 · 25.4%High 76 · 14.2%

Intervention not reported

Overall mortality · alcohol consumers with high blood pressure

The intervention showed no clear difference in overall mortality (low certainty).

1 finding from 1 review

Alcohol intake reduction for controlling hypertension 2020 · Cochrane Headline outcomes only
RR 0.72 [0.16, 3.17]
1 study · 269 participants
Low

Intervention not reported

Cardiovascular events · alcohol consumers with high blood pressure

It is very uncertain whether the intervention changes cardiovascular events (very low certainty).

1 finding from 1 review

Alcohol intake reduction for controlling hypertension 2020 · Cochrane Headline outcomes only
RR 0.8 [0.36, 1.79]
1 study · 269 participants
Very low

Intervention not reported

Decrease in systolic blood pressure (mmHg) · alcohol consumers with high blood pressure

1 finding from 1 review

Alcohol intake reduction for controlling hypertension 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 269 participants
Very low

Intervention not reported

Decrease in diastolic blood pressure (mmHg) · alcohol consumers with high blood pressure

1 finding from 1 review

Alcohol intake reduction for controlling hypertension 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 269 participants
Low

Intervention not reported

Decrease in alcohol intake (g) · alcohol consumers with high blood pressure

1 finding from 1 review

Alcohol intake reduction for controlling hypertension 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 269 participants
Low

Intervention not reported

Proportion of subjects with SBP < 140 mmHg and DBP < 90 mmHg · alcohol consumers with high blood pressure

It is very uncertain whether the intervention changes proportion of subjects with SBP < 140 mmHg and DBP < 90 mmHg (very low certainty).

1 finding from 1 review

Alcohol intake reduction for controlling hypertension 2020 · Cochrane Headline outcomes only
RR 1.21 [0.88, 1.65]
1 study · 269 participants
Very low

Beta‐blockers with partial agonist activity vs no treatment

Variation in the decrease in 24‐hour ambulatory hourly SBP (at 3 to 12 weeks) · Men and non‐pregnant women ≥ 18 years old with essential hypertension

1 finding from 1 review

Time course for blood pressure lowering of beta‐blockers with partial agonist activity 2020 · Cochrane Headline outcomes only
no estimate extracted
121 participants
Very low

Beta‐blockers with partial agonist activity vs no treatment

Variation in the decrease in 24‐hour ambulatory hourly DBP (at 3 to 12 weeks) · Men and non‐pregnant women ≥ 18 years old with essential hypertension

1 finding from 1 review

Time course for blood pressure lowering of beta‐blockers with partial agonist activity 2020 · Cochrane Headline outcomes only
no estimate extracted
121 participants
Very low

Beta‐blockers with partial agonist activity vs no treatment

Variation in the decrease in 24‐hour ambulatory hourly HR (at 3 to 12 weeks) · Men and non‐pregnant women ≥ 18 years old with essential hypertension

1 finding from 1 review

Time course for blood pressure lowering of beta‐blockers with partial agonist activity 2020 · Cochrane Headline outcomes only
no estimate extracted
71 participants
Very low

Combination therapy vs monotherapy

Total mortality · people with primary hypertension

It is very uncertain whether combination therapy changes total mortality compared with monotherapy (very low certainty).

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
RR 1.35 [0.08, 21.72]
3 studies · 568 participants
Very low

Combination with potassium‐sparing diuretics vs monotherapy

Withdrawals due to adverse events · people with primary hypertension

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 200 participants
Very low

Combination therapy vs monotherapy

Cardiovascular mortality · people with primary hypertension

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 568 participants
Very low

Combination therapy vs monotherapy

Cardiovascular events · people with primary hypertension

It is very uncertain whether combination therapy changes cardiovascular events compared with monotherapy (very low certainty).

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
RR 0.98 [0.22, 4.41]
3 studies · 568 participants
Very low

Combination therapy vs monotherapy

Serious adverse events · people with primary hypertension

It is very uncertain whether combination therapy changes serious adverse events compared with monotherapy (very low certainty).

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
RR 0.77 [0.31, 1.92]
3 studies · 568 participants
Very low

Combination therapy vs monotherapy

Withdrawals due to adverse events · people with primary hypertension

It is very uncertain whether combination therapy changes withdrawals due to adverse effects compared with monotherapy (very low certainty).

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
RR 0.85 [0.53, 1.35]
3 studies · 568 participants
Very low

Combination with potassium‐sparing diuretics vs monotherapy

Total mortality · people with primary hypertension

It is very uncertain whether combination with potassium‐sparing diuretics changes total mortality compared with monotherapy (very low certainty).

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
RR 0.24 [0.01, 5.87]
1 study · 200 participants
Very low

Combination with potassium‐sparing diuretics vs monotherapy

Cardiovascular mortality · people with primary hypertension

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 200 participants
Very low

Combination with potassium‐sparing diuretics vs monotherapy

Cardiovascular events · people with primary hypertension

It is very uncertain whether combination with potassium‐sparing diuretics changes cardiovascular events compared with monotherapy (very low certainty).

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
RR 1.45 [0.13, 15.71]
1 study · 200 participants
Very low

Combination with potassium‐sparing diuretics vs monotherapy

Serious adverse events · people with primary hypertension

It is very uncertain whether combination with potassium‐sparing diuretics changes serious adverse events compared with monotherapy (very low certainty).

1 finding from 1 review

First‐line combination therapy versus first‐line monotherapy for primary hypertension 2020 · Cochrane Headline outcomes only
RR 0.72 [0.1, 5.04]
1 study · 200 participants
Very low

Intervention not reported

Cerivastatin dose · participants with normal or abnormal lipid profiles

The review found no eligible studies for this question.

1 finding from 1 review

Cerivastatin for lowering lipids 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found